Docstoc

5420218gen

Document Sample
5420218gen Powered By Docstoc
					MATERIAL SAFETY DATA SHEET

PRODUCT NAME:

Canine Spectra 7

AS SOLD BY DURVET

A Service of

GALAXY DA2PPvL w/Sterile Diluent 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Schering-Plough Animal Health Corporation 1095 Morris Avenue Union, NJ 07083 EMERGENCY TELEPHONE NUMBER (For Human Exposure) Rocky Mountain Poison Center: (303) 595-4869 COMPANY CONTACT: Animal Health Technical Services (For Animal Adverse Events) TELEPHONE NUMBER: (800) 224-5318 TRANSPORTATION EMERGENCIES CHEMTREC: (800) 424-9300 PRODUCT NAME: Galaxy(r) DA2PPvL w/Sterile Diluent SYNONYM: N/A CAS NUMBER: N/A CHEMICAL FORMULA: N/A US VETERINARY LICENSE NO.: 165A PRODUCT TYPE: Vaccine (Biological) 2. COMPOSITION/INFORMATION ON INGREDIENTS HAZARDOUS INGREDIENTS: This product is a vaccine (biological) for use in dogs. It contains Distemper (Modified Live Virus), Adenovirus Type 2 (Modified Live Virus), Parainfluenza (Modified Live Virus), Parvovirus (Modified Live Virus), and Leptospirosis (Killed Bacteria). 3. HAZARDS IDENTIFICATION POTENTIAL HEALTH EFFECTS Eyes: N/A Skin: N/A Ingestion: N/A Inhalation: N/A Injection: In case of accidental injection, wash the site thoroughly with soap and water. While the vaccine is not considered to be a human pathogen, medical attention should be sought to address the risk of trauma-associated infection or allergic reactions. Status of tetanus immunization should be reviewed.

4. FIRST AID MEASURES EYES: Immediately flush eyes with large amounts of water for at least 15 minutes. Obtain medical attention. SKIN: Wash skin thoroughly with soap and water. Remove contaminated clothing from site of contact. Immediately contact a physician if irritation develops. INGESTION: Obtain medical attention immediately. INHALATION: Obtain medical attention immediately. INJECTION: In case of accidental injection, remove needle from injection site. Wash and disinfect area. Obtain medical attention immediately. NOTE TO PHYSICIAN: Animal health workers, research workers, and veterinarians who use inactivated bacterins or viral vaccines are at risk for accidental self-inoculations or needle stick exposures. Victims should seek medical treatment at once and inform attending physicians the name(s) of the organism(s) contained in the inactivated bacterin or viral vaccine. These types of biologic products can cause adverse allergic or hypersensitivity reactions in humans, sometimes with serious consequences, who have accidentally selfinoculated themselves or have had needle-stick exposures.

NOTE TO PHYSICIAN (CONTINUED) Allergic or anaphylactic (Type 1 Hypersensitivities) reactions can be caused by the inactivated bacteria, inactivated viruses, or other bacterin or vaccine components to which accidental needle-stick exposed humans have been previously sensitized. These reactions usually occur shortly after inoculation and are characterized by difficulty in breathing, sometimes rapid skin eruptions, or rashes, and shaking. Immediate inoculation of epinephrine is recommended to be given by attending physicians to affected humans. These emergency procedures should be followed by other supportive treatments. Delayed-type hypersensitivities may be serious in humans who have accidentally selfinoculated themselves because the hands or fingers are often involved. Clinical signs or symptoms include swelling, redness, pain, and loss of function at the inoculation sites. Microscopically, many of these adverse reactions are characterized by granulomatous inflammation. Residues of the inactivated bacterins or viral vaccines are often present in the granulomas. Neutrophils are present in the early stages of these reactions, followed by macrophages and lymphocytes. Some of the macrophages may have coalesced to form multinucleated foreign-body type giant cells in granulomas of several weeks duration. In addition to hypersensitivities, other problems which may be suffered by a victim of accidental self-inoculation or needle stick exposure are contaminated wounds at the injection site, and/or tetanus. Physical trauma of tissues may be caused by the injection needles at the vaccination sites. Accidental injection site(s) should be immediately washed thoroughly with soap and water. Bleeding, if present, from the puncture wound(s) should be encouraged as this helps drain inactivated bacterin(s) or viral vaccines(s) from the inoculation or needlestick site(s).

Successful conservative treatment with warm packs and bandaging, or splinting, or immobilization of injured parts have been reported by attending physicians. Opening, debridement, and draining of the lesion have also been reported. If a granulomatous nodule persists, or there is excessive swelling and loss of function, surgical excision of the lesions may be the only satisfactory treatment. No treatment or inadequate treatment can result in severe swelling and extensive tissue damage which unfortunately have resulted in immobilization or loss of fingers. Antibiotics may be a necessary part of the treatment of these injuries as contamination may occur. Animal health workers, research workers, veterinarians, and other people at risk using inactivated bacterins or viral vaccines should keep themselves current with tetanus toxoid immunizations. People who have had accidental self-inoculations or needle-stick exposures should be given booster tetanus toxoid vaccinations or primary series of tetanus vaccinations if deemed necessary by attending physicians. As indicated, the bacteria and viruses in inactivated bacterins and viral vaccines have been killed. Therefore, there should be no concerns involving the causation of infectious diseases by these inactivated organisms in humans. They are noninfectious. 5. FIRE FIGHTING MEASURES FLAMMABLE PROPERTIES Flash Point: N/A Autoignition: N/A Lower Explosive Limit (%): N/A Upper Explosive Limit (%): N/A FIRE AND EXPLOSION HAZARDS: None EXTINGUISHING MEDIA: N/A FIRE FIGHTING INSTRUCTIONS: N/A 6. ACCIDENTAL RELEASE MEASURES STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED: N/A 7. HANDLING AND STORAGE HANDLING PRECAUTIONS: Store at 2-7øC (35-45øF). WORK/HYGIENIC PRACTICES: Normal accepted work practices which minimize contact with skin and eyes. Avoid self inoculation or needle sticks. 8. EXPOSURE CONTROLS/PERSONAL PROTECTION ENGINEERING CONTROLS: Not required. EYE/FACE PROTECTION: Normal accepted work practices. SKIN PROTECTION: Normal accepted work practices. RESPIRATORY PROTECTION: Normal accepted work practices.

OTHER/GENERAL PROTECTION: None required. 9. PHYSICAL AND CHEMICAL PROPERTIES APPEARANCE: Dessicated vaccine cake and liquid diluent. BASIC PHYSICAL PROPERTIES Physical State: Solid/Liquid Boiling Point: N/A Melting Point: N/A Vapor Pressure: N/A Vapor Density (AIR=1): N/A Specific Gravity: N/A Molecular Weight: N/A Solubility (H2O): Complete Percent Volatility: N/A Viscosity: N/A 10. STABILITY AND REACTIVITY STABILITY: Product presents no reactivity hazard. CONDITIONS TO AVOID (STABILITY): N/A HAZARDOUS DECOMPOSITION PRODUCTS: N/A HAZARDOUS POLYMERIZATION: N/A 11. TOXICOLOGICAL INFORMATION ACUTE STUDIES Eye Effects: N/A Skin Effects: N/A Oral Effects: N/A Inhalation Effects: N/A MISCELLANEOUS TOXICOLOGICAL INFORMATION Effects Of Overexposure: See (above) NOTE TO PHYSICIAN. 12. ECOLOGICAL INFORMATION

N/A 13. DISPOSAL CONSIDERATIONS PRODUCT/CONTAINER DISPOSAL: Burn containers and all unused contents. 14. TRANSPORT INFORMATION SHIPPING PAPER DESCRIPTION: N/A 15. REGULATORY INFORMATION N/A

16. OTHER INFORMATION N/A DISCLAIMER OF EXPRESSED AND IMPLIED WARRANTIES Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequences of its use. Each individual should make a determination as to the suitability of the information for their particular purpose (s). Schering-Plough Animal Health M a t e r i a l S a f e t y D a t a S h e e t Galaxy(r) DA2PPvL w/Sterile Diluent Rev. date 12/28/98 1


				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:2
posted:8/13/2009
language:English
pages:6